Table 2.

Detection of SARS-CoV-2 RNAemia, N-antigenemia and anti-RBD IgG stratified by time since COVID-19 symptoms onset in critically ill patients.

Combination of qualitative results for SARS-CoV-2 RNAemia or N-antigenemia and anti-RBD IgGs (total no. of specimens)	Time evolved since symptoms onset
	Week 1. no. of specimens	Week 2. no. of specimens	Week 3. no. of specimens	≥ Week 4. no. of specimens
Detection of viral RNAemia and anti-RBD IgG (n = 25)	4	12	7	2
Detection of Detection of viral RNAemia and lack of anti-RBD IgG (n = 12)	5	5	1	1
Absence of viral RNAemia and detection of anti-RBD IgG (n = 272)	4	40	83	145
Absence of viral RNAemia and lack of anti-RBD IgG (n = 29)	2	9	4	14
Detection of viral N-antigenemia and anti-RBD IgG (n = 24)	6	16	0	2
Detection of viral N-antigenemia and lack of anti-RBD IgG (n = 19)	6	9	2	2
Absence of viral N-antigenemia and detection of anti-RBD IgG (n = 273)	2	36	90	145
Absence of viral N-antigenemia and lack of anti-RBD IgG (n = 22)	1	5	3	13

RBD receptor binding domain.